Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal and metabolic diseases. It has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was founded in 2007 an
|Shares Outstanding||EPS||-2.73||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-35.61%||Sales Growth - Q/Q||-7.19%||P/E||-1.59|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-3.46%||ROE||-6.28%||ROI|
|Current Ratio||5.12||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.34|
|Gross Margin||Operating Margin||-15.85%||Net Profit Margin||-12.59%||Dividend Payout Ratio|
|Cash From Financing Activities||300 K||Cash From Investing Activities||-1.05 M||Cash From Operating Activities||-8.21 M||Gross Profit|
|Net Profit||-3.5 M||Operating Profit||-3.49 M||Total Assets||105.4 M||Total Current Assets||101.91 M|
|Total Current Liabilities||19.91 M||Total Debt||Total Liabilities||47.4 M||Total Revenue||5.88 M|
|High 52 week||7.9||Low 52 week||1.66||Last close||2.23||Last change||-4.29%|
|RSI||69.29||Average true range||0.19||Beta||1.5||Volume||61.04 K|
|Simple moving average 20 days||10.4%||Simple moving average 50 days||-8.8%||Simple moving average 200 days||-41.66%|
|Performance Week||-7.08%||Performance Month||3.72%||Performance Quart||-39.89%||Performance Half||-52.04%|
|Performance Year||-68.59%||Performance Year-to-date||24.58%||Volatility daily||5.5%||Volatility weekly||12.3%|
|Volatility monthly||25.21%||Volatility yearly||87.35%||Relative Volume||187.64%||Average Volume||352.07 K|
|New High||New Low|
2019-06-25 20:33:43 | Is Ardelyx Inc ARDX A Good Stock To Buy?
2019-05-30 09:00:00 | Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
2019-05-16 12:56:15 | Why Ardelyx, Inc.'s NASDAQ:ARDX CEO Pay Matters To You
2019-05-07 18:45:10 | Ardelyx ARDX Reports Q1 Loss, Misses Revenue Estimates
2019-05-07 17:34:27 | Ardelyx: 1Q Earnings Snapshot
2019-05-07 16:02:00 | Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
2019-05-07 10:30:02 | Ardelyx ARDX Expected to Beat Earnings Estimates: Should You Buy?
2019-05-06 09:55:01 | What's in the Cards for Axon Enterprise AAXN Earnings?
2019-03-06 16:05:00 | Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights
2019-03-01 14:54:24 | An Examination Of Ardelyx, Inc. NASDAQ:ARDX
2019-02-21 08:00:00 | Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
2019-02-12 08:25:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth
2019-01-18 09:20:26 | Ardelyx, Inc. NASDAQ:ARDX Is Trading At A 28.78% Discount
2018-12-18 02:50:44 | Ardelyx Inc ARDX: Are Hedge Funds Right About This Stock?
2018-11-26 14:26:07 | What Type Of Shareholder Owns Ardelyx Inc’s NASDAQ:ARDX?
2018-11-07 18:12:34 | Ardelyx: 3Q Earnings Snapshot
2018-11-07 16:05:00 | Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
2018-10-16 07:50:00 | Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
2018-09-18 08:19:01 | How Does Investing In Ardelyx Inc NASDAQ:ARDX Impact Your Portfolio?
2018-08-17 08:20:00 | Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx — Fundamental Analysis, Key Performance Indications
2018-08-16 15:06:47 | Edited Transcript of ARDX earnings conference call or presentation 7-Aug-18 8:30pm GMT
2018-08-07 16:51:35 | Ardelyx: 2Q Earnings Snapshot
2018-08-07 16:01:00 | Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
2018-08-07 14:30:00 | Ardelyx, Inc. to Host Earnings Call
2018-08-01 06:30:00 | Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
2018-06-26 07:10:00 | Free Technical Reports on Array BioPharma and Three Additional Biotech Equities
2018-05-31 07:40:00 | Consolidated Research: 2018 Summary Expectations for CorVel, Consol Energy, Ardelyx, Aevi Genomic Medicine, Proofpoint, and Brink's — Fundamental Analysis, Key Performance Indications
2018-05-29 06:30:00 | Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
2018-05-23 13:39:00 | Why Ardelyx Inc. Is Down by Double Digits for a Second Day in a Row
2018-05-22 18:00:00 | Ardelyx Announces Pricing of Public Offering of Common Stock
2018-05-21 16:02:00 | Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
2018-05-21 16:01:00 | Ardelyx Announces Proposed Public Offering of Common Stock
2018-05-08 17:56:31 | Ardelyx: 1Q Earnings Snapshot
2018-05-08 16:05:00 | Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights
2018-04-05 08:15:00 | Analysis: Positioning to Benefit within Euronet Worldwide, Innospec, Zosano Pharma, Ardelyx, Crown Castle International, and Aldeyra Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results
2018-03-19 06:30:00 | Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
2018-03-14 16:34:31 | Ardelyx posts 4Q profit